Masato Yamamoto, MD, PhD

Eugene C. and Gail V. Sit Chair in
Pancreatic and Gastrointestinal Cancer Research
Vice-Chair of Surgical Science,

Masato Yamamoto

Contact Info

Office Phone 612-624-9131;

Fax 612-624-9080

Office Address:
Department of Surgery
11-210 MMT Bldg
515 Delaware St SE
Minneapolis, MN 55455

Mailing Address:
Surgery BTR
MMC 195 Mayo
420 Delaware St SE
Minneapolis, MN 55455

Administrative Assistant Name
Kelli Tourand

Administrative Phone

Administrative Email

M.D., Osaka University School of Medicine, 1987

PhD, Osaka University School of Medicine, 1997



Cancer gene-therapy and virotherapy


Research Summary/Interests

  • Cancer gene therapy with Adenovirus Vector
  • Conditionally replicative adenovirus for the treatment of cancer
  • Non-invasive in vivo molecular imaging
  • Gene therapy of gastrointestinal diseases, pancreatic cancer, esophageal cancer, prostate cancer, breast cancer, and multiple myeloma

Cancer gene-therapy and virotherapy
Our goal is to develop clinically usable gene-/viro-therapy modalities for solid tumors, e.g. GI cancers including pancreatic cancer. Our group has been developing cancer therapeutics with adenovirus as gene delivery tool. Current gene therapy modalities for cancer have not achieved the expected therapeutic efficiency due to disease related obstacles. Our lab is developing advanced version of adenovirus vectors and oncolytic adenoviruses by employing virological advance. We perform extensive vector engineering and produce the viruses/vectors to overcome the issues impeding clinical realization of this kind of therapeutics. Recent advances include 1) Development of adenovirus targeting ligand library and its application to the targeted delivery upon systemic administration, 2) Theranostics enables tumor imaging and tumor selective radiotherapy employing sodium-iodine symporter, 3) Combination viro-therapy with INF-alpha expressing oncolytic adenovirus and chemoradiation, 4) Development of cancer stem cell targeted oncolytic adenovirus.


  • Le LP, Le HN, Nelson AR, Matthews DA, Yamamoto M, Curiel DT. Core Labeling of Adenovirus with EGFP. Virology (in press)
  • Bauerschmitz GJ, Kanerva A, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A. Triple targeted oncolytic adenoviruses featuring the Cox2 promoter, E1A trans-complementation and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (in press)
  • Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S, Curiel DT, Yamamoto M. Dynamic Monitoring of Oncolytic Adenovirus In Vivo by Genetic Capsid Labeling. J Natl Cancer Inst. 2006 Feb 1;98(3):203-14.
  • Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M. Non-invasive Visualization of Adenovirus Replication with a Fluorescent Reporter in the E3 Region. Cancer Res. 2005 Nov 15;65(22):10154-8.
  • Stoff-Khalili MA, Stoff A, Rivera AA, Mathis JM, Everts M, Wang M, Kawakami Y, Waehler R, Mathews QL, Yamamoto M, Rocconi RP, Siegal GP, Richter DF, Dall P, Zhu ZB, Curiel DT. Gene Transfer to Carcinoma of the Breast with Fiber-Modified Adenoviral Vectors in a Tissue Slice Model System. Cancer Biol Ther. 2005 Nov 8;4(11)
  • Masato Yamamoto, Norihiro Nishimoto, Julia Davydova, Tadamitsu Kishimoto and David T. Curiel. Suppressor of Cytokine Signaling-1 (SOCS-1) Expression by Infectivity Enhanced Adenoviral Vector Inhibits IL-6 Dependent Proliferation of Multiple Myeloma Cells. Cancer Gene Therapy 2005 Aug 5; [Epub ahead of print].
  • Masato Yamamoto and David T. Curiel. Cancer Gene Therapy. Technology in Cancer Research and Treatment 2005 Aug;4(4):315-30.
  • Gommans WM, van Eert SJ, McLaughlin PMJ, Harmsen MC, Yamamoto M, Curiel DT, Haisma HJ, Rots MG. The carcinoma-specific Epithelial Glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Therapy 2005 Aug 12; [Epub ahead of print]
  • Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, Curiel DT, Zhu ZB. Evaluation of tumor-specific promoter activities in melanoma. Gene Ther. 2005 Feb;12(4):330-8.
  • Huang CM, Shi ZK, DeSilva TS, Yamamoto M, Van Kampen KR, Elmets CA, Tang DC. A Differential Proteome in Tumors Suppressed by an Adenovirus-based Skin Patch Vaccine Encoding Human Carcinoembryonic Antigen. Proteomics 2005 Mar;5(4):1013-23.
  • Tekant Y, Davydova J, Ramirez PJ, Curiel DT, Vickers SM, Yamamoto M. Oncolytic adenoviral therapy in gallbladder carcinoma. SURGERY 2005 May:137(5):527-35.
  • Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004 Dec 15;10(24):8697-703.
  • Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, Wang M, Nettelbeck DM, Tsuruta Y, Yamamoto M, Dall P, Hemminki A, Curiel DT. A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer. Clin Cancer Res. 2005 Feb 1;11(3):1327-1335.
  • Liang Q, Yamamoto M, Curiel DT, Herschman HR. Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene. Mol Imaging Biol. 2004 Nov-Dec;6(6):395-404.
  • Ono HA, Davydova JG, Adachi Y, Takayama K, Barker SD, Reynolds PN, Krasnykh VN, Kunisaki C, Shimada H, Curiel DT, Yamamoto M. Promoter-Controlled Infectivity Enhanced Conditionally Replicative Adenoviral Vectors for the Treatment of Gastric Cancer. J Gastroenterol. 2005 Jan;40(1):31-42.
  • Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ, Yamamoto M, Adachi Y, Takayama K, Dall P, Curiel DT. Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med. 2004 Nov; 6(11) 1281?1289.
  • Buchsbaum DJ, Cahudhuri TR, Yamamoto M and Zinn KR. Gene expression imaging with radiolabeled peptides. Annals of Nuclear Medicine 2004; 18(4): 275?283.
  • Masato Yamamoto. Conditionally Replicative Adenovirus for Gastrointestinal Cancers. Expert Opinion on Biological Therapy. 2004 Aug;4(8):1241-50.
  • Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM. Combining High Selectivity of Replication with Fiber Chimerism for Effective Adenoviral Oncolysis of CAR-Negative Melanoma Cells. Gene Therapy, 2004 Dec 1; 11(23)1694 - 1702.
  • Davydova J, Le LP, Gavrokova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced Cyclooxygenase-2-based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma. Cancer Research. 2004 Jul 15:64(12):4319-27.
  • Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT. Fluorescently Labeled Adenovirus with pIX-EGFP for Vector Detection. Molecular Imaging, 2004 Apr;3(2):105-16.
  • Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd, Yamamoto M, Alvarez RD, Curiel DT. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther. 2004 Apr;11(7):645-8. (My name miss-spelled as Yamaoto, erratum submitted)
  • Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamamoto M, Li F, Alvarez RD, Curiel DT. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 2004 Apr;11(4):256-62. (My name miss-spelled as Yamaoto, erratum submitted)
  • Lam JT, Kenerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Wang M, Barnes MN, Alvarez RD, Siegal GP, Curiel DT and Hemminki A. Evaluation of Five Replicative adenoviruses for Ovarian Cancer Therapy. Journal of Gene Medicine. 2004 Oct;6(12)1333-1342.
  • F Yamamoto M, Curiel DT. Nonreplicating DNA viral vectors for suicide gene therapy: the adenoviral vectors. Methods Mol Med. 2004;90:61-70.
  • Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. 2004 Mar;11(6):552-9.
  • Buskens CJ, Marsman WA, Wesseling JG, Offerhaus GJ, Yamamoto M, Curiel DT, Bosma PJ, van Lanschot JJ. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann Surg. 2003 Dec;238(6):815-24.
  • Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM and Curiel DT. Infectivity Enhanced, Cyclooxygenase-2 Promoter-Based Conditionally Replicative Adenovirus for Pancreatic Cancer. Gastroenterology. 2003 October; 125(4):1203-1218.
  • Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT. Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma. Melanoma Res. 2003 Jun;13(3):287-292.
  • Yamamoto M, Davydova J, Takayama K, Alemany R and Curiel DT. Transcription Initiation Activity of Adenoviral Left End Sequence in E1 Deleted Adenoviral Vectors. Journal of Virology. 2003 Jan 77(2):1633?1637.
  • Nagi P, Vickers S, Davydova J, Barker S, Adachi Y, Takayama K, Krasnykh V, Curiel DT and Yamamoto M. Development of a Therapeutic Adenoviral Vector for Cholangiocarcinoma Combining Infectivity-Enhancement and Tumor-Restricted Gene Expression. Journal of Gastrointestinal Surgery, 7(3):364-371.
  • Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med. 2003 Apr;5(4):300-10.
  • Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenoviral E3 gene improves the oncolytic potency of conditionally replicative adenoviruses. Clinical Cancer Research. 2002 Nov;8(11):3348-59.
  • Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, Li H, Reynolds PN, Dmitriev I, Vickers SM, Huibregtse K and Curiel DT. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 2001 Dec;8(12):990-6.
  • Adachi Y, Reynolds PN, Yamamoto M, Minghui W, Takayama K, Matsubara S, Muramatsu T and Curiel DT. A Midkine promoter-based conditionally replicative adenovirus for the treatment of of pediatric solid tumors and bone marrow tumor purging. Cancer Research. 2001 Nov 1:61(21):7882-7888.
  • Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and Its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Cancers. Molecular Therapy 2001 Mar;3(3):385-94.
  • Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Arafat W, Barker SB, Wang M, Mahasreshti P, Gonzalez Baron M, Pustilnik T, Siegal G, Alvarez R, Curiel DT. Strategies To Accomplish Targeted Expression Of Transgenes In Ovarian Cancer For Molecular Therapeutic Applications. Clinical Cancer Research. Clin Cancer Res. 2001 Aug;7(8):2496-504.
  • Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT. Midkine promoter-bated adenoviral vector gene delivery for pediatric solid tumors. Cancer Res. 2000 Aug 15;60(16):4305-10.
  • Yamamoto M, Hayashi N, Takehara T, Ueda K, Mita E, Tatsumi T, Sasaki Y, Kasahara A, Hori M. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology 1999 Jul;30(1):300-7.
  • Yamamoto M, Hayashi N, Miyamoto Y, Takehara T, Mita E, Seki M, Fusamoto H, Kamada T. In vivo transfection of hepatitis C virus complementary DNA into rodent liver by asialoglycoprotein receptor mediated gene delivery. Hepatology 1995 Sep;22(3):847-55.
  • Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Research 1996 Jul 1;56(13):3004-9.
  • Tatsumi T, Takehara T, Katayama K, Mochizuki K, Yamamoto M, Kanto T, Sasaki Y, Kasahara A, Hayashi N. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997 May;25(5):1108-14.
  • Takehara T, Hayashi N, Yamamoto M, Miyamoto Y, Fusamoto H, Kamada T. In vivo gene transfer and expression in rat stomach by submucosal injection of plasmid DNA. Human Gene Therapy 1996 Mar 20;7(5):589-93.
  • Yamamoto M, Hayashi N, Miyamoto Y, Kamada T. HCV gene transfected animal using receptor mediated gene delivery. Nippon Rinsho 1995 Sep;53 Suppl:107-11.
  • Takehara T, Hayashi N, Miyamoto Y, Yamamoto M, Mita E, Fusamoto H, Kamada T. Expression of the hepatitis C virus genome in rat liver after cationic liposome-mediated in vivo gene transfer. Hepatology 1995 Mar;21(3):746-51.
  • Masato Yamamoto, Masayoshi Horimoto, Eiji Mita, Haruya Meren, Hideyuki Fusamoto and Tomozumi Kuroda. A case of rupture of mesenteric vein due to idiopathic portal hypertension with arterio-portal fistula. (Japanese) Proceeding of Abdominal Emergency Medicine 1989 9(4):647-650.
  • Miura Y, Yamasaki S, Davydova J, Brown E, Aoki K, Vickers SM, and Yamamoto M. Infectivity-Selective Oncolytic Adenovirus Developed by High-throughput Screening of Adenovirus-formatted Library. Molecular Therapy. 2012. (Pubmed ahead of print)
  • Yamamoto M, Curiel DT. 2010. Current Issues and Future Directions of Oncolytic Adenoviruses. Mol Ther. Feb;18(2):243-50.
  • Li HJ, Everts M, Yamamoto M, Curiel DT, and Herschman HR. 2009. Combined transductional untargeting/retargeting and transcriptional restriction enhance adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Res. Jan 15;69(2):554-64.